UBS Group
PGNX

UBS Group’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

UBS Group’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-25,005
Closed -$95K – 8663
2020
Q1 		$95K Sell
25,005
-44,678
-64% -$192K ﹤0.01% 5338
2019
Q4 		$355K Sell
69,683
-95,057
-58% -$503K ﹤0.01% 5148
2019
Q3 		$833K Buy
164,740
+82,609
+101% +$412K ﹤0.01% 4119
2019
Q2 		$507K Buy
82,131
+43,011
+110% +$207K ﹤0.01% 4290
2019
Q1 		$181K Sell
39,120
-232,527
-86% -$1.05M ﹤0.01% 4667
2018
Q4 		$1.14M Buy
271,647
+264,601
+3,755% +$1.35M ﹤0.01% 3552
2018
Q3 		$44K Buy
7,046
+2,997
+74% +$23K ﹤0.01% 6258
2018
Q2 		$33K Sell
4,049
-113,995
-97% -$870K ﹤0.01% 6327
2018
Q1 		$880K Buy
118,044
+115,197
+4,046% +$766K ﹤0.01% 3817
2017
Q4 		$17K Sell
2,847
-23,200
-89% -$141K ﹤0.01% 6695
2017
Q3 		$192K Buy
26,047
+14,229
+120% +$90.4K ﹤0.01% 4874
2017
Q2 		$80K Sell
11,818
-132
-1% -$974 ﹤0.01% 5319
2017
Q1 		$113K Sell
11,950
-31,387
-72% -$313K ﹤0.01% 5000
2016
Q4 		$375K Buy
43,337
+14,261
+49% +$105K ﹤0.01% 4324
2016
Q3 		$184K Sell
29,076
-13,070
-31% -$79K ﹤0.01% 4603
2016
Q2 		$178K Buy
42,146
+25,596
+155% +$124K ﹤0.01% 4621
2016
Q1 		$72K Sell
16,550
-111,221
-87% -$495K ﹤0.01% 5220
2015
Q4 		$783K Buy
127,771
+111,971
+709% +$734K ﹤0.01% 3599
2015
Q3 		$90K Buy
15,800
+8,700
+123% +$66.8K ﹤0.01% 5327
2015
Q2 		$53K Buy
7,100
+2,000
+39% +$12.1K ﹤0.01% 5970
2015
Q1 		$31K Sell
5,100
-300
-6% -$1.89K ﹤0.01% 6521
2014
Q4 		$41K Buy
+5,400
New +$32.3K ﹤0.01% 6742

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

UBS Group's PGNX Position: Q2 2020 in Review

UBS Group sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 25,005 shares — an estimated $95K sold.

UBS Group first reported a position in PGNX in Q4 2014 and held it in 22 quarters. The position peaked at $1.14M in Q4 2018. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • UBS Group reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • UBS Group sold 25,005 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $95K.
  • UBS Group first reported a position in Progenics Pharmaceuticals Inc in Q4 2014 and held it in 22 quarters.
  • UBS Group's Progenics Pharmaceuticals Inc position peaked at $1.14M in Q4 2018.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on UBS Group's 13F filing for Q2 2020, filed 31 Jul 2020.